Tevogen Inc. (TVGNW) stock
TVGNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as TVGN
$0.09+0.01 (+18.24%)
Close on Oct 30, 2026Market cap $38.42MP/E –Yield –
Tevogen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Tevogen's operating income for the twelve months ending Jun 30, 2026 was -$21.40M. For fiscal 2025 it was -$26.14M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.14M | – |
| FY2024 | Dec 31, 2024 | -$53.56M | – |
| FY2023 | Dec 31, 2023 | -$8.84M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.36M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.36M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.09M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.52M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.01M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.33M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.32M | – |